Avidity Biosciences, Inc. (RNA)
- Previous Close
24.16 - Open
24.20 - Bid 24.47 x 200
- Ask 24.77 x 200
- Day's Range
24.06 - 24.81 - 52 Week Range
4.82 - 27.66 - Volume
39,709 - Avg. Volume
1,202,514 - Market Cap (intraday)
1.957B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-2.91 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
46.71
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
www.aviditybiosciences.comRecent News: RNA
Performance Overview: RNA
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNA
Valuation Measures
Market Cap
1.93B
Enterprise Value
1.34B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
184.52
Price/Book (mrq)
3.85
Enterprise Value/Revenue
140.22
Enterprise Value/EBITDA
-5.74
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.24%
Return on Equity (ttm)
-39.34%
Revenue (ttm)
9.56M
Net Income Avi to Common (ttm)
-212.22M
Diluted EPS (ttm)
-2.91
Balance Sheet and Cash Flow
Total Cash (mrq)
595.35M
Total Debt/Equity (mrq)
1.97%
Levered Free Cash Flow (ttm)
-86.66M